Table 1 Baseline Characteristics of Patients From the GOYA Trial Who Completed the EORTC QLQ-C30 and FACT-Lym LymS at Both Baseline and Cycle 3 Day 1
Characteristic | N = 1,132 |
|---|---|
Age, y | |
Mean (SD) | 58.5 (13.6) |
Median [Min, Max] | 61.0 [18.0, 86.0] |
TMTV, cm3 | |
Mean (SD) | 662 (968) |
Median [Min, Max] | 337 [1.04, 10 600] |
Missing | 80 (7.1%) |
Sex | |
Female | 529 (46.7%) |
Male | 603 (53.3%) |
Bone marrow involvement | |
Positive | 118 (10.4%) |
Negative | 994 (87.8%) |
Indeterminate | 11 (1.0%) |
Missing | 9 (0.8%) |
BCL2 mutational status | |
Positive | 282 (24.9%) |
Negative | 313 (27.7%) |
Missing | 537 (47.4%) |
Cell of origin | |
ABC | 196 (17.3%) |
GCB | 428 (37.8%) |
Unclassified | 117 (10.3%) |
Missing | 391 (34.5%) |
ECOG PS | |
0–1 | 1004 (88.7%) |
2–3 | 127 (11.2%) |
Missing | 1 (0.1%) |
Ann Arbor Stage | |
I-II | 277 (24.5%) |
III-IV | 855 (75.5%) |
Missing | 0 (0%) |
LDH, units/L | |
≤ 280 | 565 (49.9%) |
> 280 | 564 (49.8%) |
Missing | 3 (0.3%) |
Extranodal site | |
0–1 | 744 (65.7%) |
2–3 | 324 (28.6%) |
4 | 32 (2.8%) |
> 4 | 32 (2.8%) |
IPI score | |
High/high-intermediate | 485 (42.8%) |
Low/low-intermediate | 647 (57.2%) |
Missing | 0 (0%) |